Steven A. Kriegsman -
Chairman and Chief Executive Officer
Mr. Kriegsman has been CytRx Corporation's President and Chief Executive Officer since 2002 and its Chairman since 2014. He also serves as a director of Galena Biopharma, Inc. (Nasdaq: GALE) and Chairman of Galena's Compensation and Transaction Committees. He previously served as Director and Chairman of Global Genomics from June 2000. Mr. Kriegsman is an inactive Chairman and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Advanced Tissue Sciences, and Maxim Pharmaceuticals. Mr. Kriegsman has a BS degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman is a graduate of the Stanford Law School Directors' College. Mr Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. He served as a Director and is the former Chairman of the Audit Committee of Bradley Pharmaceuticals, Inc. (NYSE, the company has since been sold). In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr. Kriegsman has been a guest speaker and lecturer at various universities including California Institute of Technology (Caltech), Brown University and New York University. Mr. Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, the California Health Initiative, the American Association of Dance Companies, and the Palisades-Malibu YMCA.
Daniel Levitt, M.D., Ph.D. -
Executive Vice President and Chief Medical Officer
Dr. Levitt brings more than 24 years of senior management experience, spearheading numerous drug development programs to commercialization at leading biotechnology and pharmaceutical companies. Prior to joining CytRx, Dr. Levitt served as Executive Vice President, Research and Development at Cerimon Pharmaceuticals, Inc., where he implemented three Phase III pivotal trials. Prior to that, he was Chief Medical Officer and Head of Clinical and Regulatory Affairs at Dynavax Technologies Corporation, managing clinical trials for four programs and overseeing multi-country regulatory strategies. Dr. Levitt was also Chief Operating Officer and Head of Research and Development at Affymax, Inc., where he spearheaded all aspects of that company’s research, development, and commercialization operations, and he spent six years at Protein Design Labs, Inc., completing his tenure as that firm’s President and Head of Research and Development. Dr. Levitt’s past experience includes a position as Head of Drug Development at Geron Corporation, and Head of the Cytokine Development Unit and Global Clinical Oncology at Sandoz Pharmaceuticals Ltd., and as Director, Clinical Oncology and Immunology at Hoffmann-LaRoche, Inc. Dr. Levitt graduated Magna Cum Laude and Phi Beta Kappa with a Bachelor of Arts degree from Brandeis University. He earned both his M.D. and his Ph.D. in Biology from the University of Chicago Pritzker School of Medicine. Dr. Levitt has received 10 major research awards and authored or co-authored nearly 200 papers and abstracts.
Olivia C. Ware -
Chief Commercial Officer
Ms. Ware brings more than 20 years of biotechnology and pharmaceutical experience. Prior to joining CytRx in January, 2016, she was at Genentech, Inc. from April 1997 to January 2010, where she rose to Senior Director of Oncology and was responsible for the initial commercial launch of Avastin in the U.S. Prior to this, she was head of Herceptin marketing and previously held a number of other positions in the commercial organization. Ms. Ware was a Senior Director in the Product Portfolio Management Group, managing approximately 20 senior leaders responsible for building and leading the cross-functional drug development teams that developed and implemented strategic plans and guided the drug development processes for the oncology portfolio at Genentech. From January 2010 until December 2015, Ms. Ware worked as an independent consultant providing strategic support and management expertise for global product launches, market assessments and coaching and mentoring for team leaders and executive teams. Previously, Ms. Ware worked in healthcare consulting for Baxter Healthcare; and was the western region general manager for Apria Healthcare, a large national home healthcare company. Ms. Ware has an MBA in Finance and Marketing, from the University of North Carolina at Chapel Hill and a B.A. from Davidson College, Davidson, North Carolina.
John Y. Caloz -
Chief Financial Officer
Mr. Caloz has an accomplished history of providing senior financial leadership in the life sciences sector, including as Chief Financial Officer of Occulogix, Inc, a NASDAQ listed, a medical therapy company. Prior to that, Mr. Caloz served as Chief Financial Officer of IRIS International Inc., a Chatsworth, CA based medical device manufacturer. He served as Chief Financial Officer of San Francisco-based Synarc, Inc., a medical imaging company, and from 1993 to 1999 he was Senior Vice President, Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, Canada, which was acquired by MDS Inc. in 1999. Mr. Caloz was a partner at Rooney, Greig, Whitrod, Filion & Associates of Saint Laurent, Quebec, Canada, a firm of Chartered Accountants specializing in research and development and high tech companies, from 1983 to 1993. Mr. Caloz, a Chartered Accountant, holds a degree in Accounting from York University, Toronto, Canada.
Benjamin S. Levin -
General Counsel, Vice President of Legal Affairs and Corporate Secretary
Until 2004, Mr. Levin practiced at O'Melveny & Myers LLP in Los Angeles as a transactional attorney. He worked in a wide variety of disciplines including mergers and acquisitions, public and private securities offerings, corporate governance and SEC reporting and disclosure. Mr. Levin graduated from Stanford Law School with distinction, and graduated Phi Beta Kappa from the Massachusetts Institute of Technology with a S.B. in Economics.
Scott Wieland, Ph.D. -
Senior Vice President of Drug Development
Prior to joining CytRx, Dr. Wieland was Vice President of Drug Development and Regulatory Affairs, with clinical and regulatory oversight of a Alzheimer's disease development program. His fifteen years of experience in the biopharmaceutical industry has provided Scott a balanced approached to developing products for the market place. His experience ranges across all aspects of drug development with a focus on neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and stroke. Scott received a M.A. and Ph.D. in biopsychology from the University of Arizona and a M.B.A. from Webster University.
David J. Haen -
Vice President, Business Development
Graduated Cum Laude from Loyola Marymount University in Business and Communications. Mr. Haen assists in negotiating strategic alliances, mergers and acquisitions, and in-licensing and out-licensing of product opportunities.
Felix Kratz -
Vice President, Drug Discovery
Dr. Kratz is a medicinal chemist with more than 25 years of pertinent experience in the preclinical development of anticancer drugs, prodrugs and protein conjugation chemistry and profound knowledge of translational research from the laboratory to the clinic. He has successfully transferred aldoxorubicin, CytRx clinical lead compound, from bench to bedside that is based on an innovative drug delivery platform exploiting circulating albumin as a tumor-specific drug carrier. Felix Kratz graduated in Chemistry from the University of Heidelberg with Magna Cum Laude. Prior to joining CytRx Corporation he established the Division of Macromolecular Prodrugs at the Tumor Biology Center Freiburg. He serves on the Editorial Board for Bioconjugate Chemistry, Current Medicinal Chemistry, Current Bioactive Compounds, and Pharmacology & Pharmacy and has authored approximately 260 scientific publications, book articles and proceedings and is the inventor of over 20 patents and patent applications. As Vice President he heads the CytRx Drug Discovery Branch located in the Innovation Center Freiburg, Germany.
Carrie Helland, MBA, PMP -
Vice President, Project Management and Manufacturing
Ms. Helland manages CytRx's drug development programs. Prior to joining CytRx, Ms. Helland was with Amgen Inc., where she was a member of the commercial development team for Prolia™/ XGEVA™ (denosumab). While at Amgen, Ms. Helland also managed global manufacturing initiatives supporting late-stage clinical and commercial products. Following Amgen, Ms. Helland served as the Senior Program Manager at IRIS International Inc., where she managed new product development including NADiA® ProsVue™ and was involved with mergers and acquisitions. Ms. Helland holds an MBA from Pepperdine University and a BA in Chemistry and Biochemistry from the University of Kansas.